u/JusaVaan · 15d agono track record yet
Compass Pathways (CMPS)-first FDA-approved psychedelic to market
CMPS's proprietary psilocybin therapy Comp360 is expected to receive FDA approval by end of 2024, likely within weeks. With a compressed timeline post-NDA submission, FDA Priority Voucher in hand, large successful Phase 3 trials, and a $1.5B market cap, the stock appears significantly undervalued relative to potential revenue from a 2-3% penetration of the 4M TRD patient market plus the 21M PTSD population.
At post $12.00Now $11.18-6.8% since postedas of Oct 23, 4:45 PM ET
1d—
3d-3.9%
1w-10.4%
1m—
3m—
6m—
1y—